Sale!

GARS1 Gene CMT2D Genetic Test

Original price was: $700.Current price is: $500.

-29%

The GARS1 Gene CMT2D NGS Genetic DNA Test is a cutting-edge genetic screening that identifies mutations in the GARS1 gene associated with Charcot-Marie-Tooth disease type 2D. This comprehensive test utilizes Next-Generation Sequencing (NGS) technology to provide accurate detection of genetic variations responsible for this inherited neurological disorder. Patients experiencing symptoms like muscle weakness, foot deformities, or sensory loss in extremities should consider this test. The analysis helps confirm diagnosis, guide treatment decisions, and provide crucial information for family planning. Results are typically available within 3-4 weeks from sample collection. This test is priced at $500 USD with a regular price of $700 USD, making advanced genetic testing accessible for comprehensive neurological evaluation.

Trusted Testing. Expert Care. Guaranteed Privacy.

  • Accredited and Trusted
  • Expert Scientists, Advanced Technology
  • Data Privacy Guaranteed
Guaranteed Safe Checkout

GARS1 Gene CMT2D NGS Genetic DNA Test

Comprehensive Genetic Testing for Charcot-Marie-Tooth Disease Type 2D

The GARS1 Gene CMT2D NGS Genetic DNA Test represents a breakthrough in neurological genetic diagnostics, offering precise detection of mutations associated with Charcot-Marie-Tooth disease type 2D. This advanced testing methodology provides crucial insights for patients and healthcare providers dealing with inherited peripheral neuropathies.

What is the GARS1 Gene CMT2D Test?

This specialized genetic test focuses on analyzing the GARS1 gene, which encodes glycyl-tRNA synthetase – an essential enzyme involved in protein synthesis. Mutations in this gene are directly linked to Charcot-Marie-Tooth disease type 2D (CMT2D), a hereditary motor and sensory neuropathy that primarily affects the peripheral nervous system. The test utilizes Next-Generation Sequencing (NGS) technology to comprehensively examine the entire GARS1 gene for pathogenic variants.

What Does the Test Detect?

The GARS1 Gene CMT2D NGS Genetic DNA Test identifies:

  • Point mutations in the GARS1 gene coding regions
  • Small insertions and deletions affecting gene function
  • Pathogenic variants associated with CMT2D inheritance
  • Genetic markers for autosomal dominant Charcot-Marie-Tooth disease
  • Specific mutations impacting peripheral nerve function

Who Should Consider This Test?

Clinical Indications and Symptoms

This genetic test is recommended for individuals presenting with:

  • Progressive muscle weakness in hands and feet
  • Sensory loss in extremities
  • Foot deformities such as high arches or hammertoes
  • Difficulty with fine motor skills
  • Family history of peripheral neuropathy
  • Unexplained walking difficulties or balance problems
  • Reduced tendon reflexes
  • Muscle atrophy in lower legs and hands

Benefits of GARS1 Genetic Testing

Undergoing the GARS1 Gene CMT2D NGS Genetic DNA Test provides numerous advantages:

  • Accurate Diagnosis: Confirms or rules out CMT2D with high precision
  • Family Planning Guidance: Provides crucial information for genetic counseling
  • Treatment Planning: Helps neurologists develop targeted management strategies
  • Early Intervention: Enables proactive symptom management
  • Genetic Counseling: Supports informed decision-making for at-risk family members
  • Disease Progression Monitoring: Establishes baseline for ongoing care

Understanding Your Test Results

Interpretation Guidelines

Your genetic test results will fall into one of several categories:

  • Positive Result: Indicates the presence of a known pathogenic mutation in the GARS1 gene, confirming CMT2D diagnosis
  • Negative Result: No pathogenic variants detected, though clinical correlation remains essential
  • Variant of Uncertain Significance (VUS): Identifies genetic changes with unknown clinical impact requiring further evaluation
  • Carrier Status: Determines inheritance patterns for family members

All results are accompanied by comprehensive interpretation from our board-certified genetic specialists and neurologists. We recommend discussing results with your healthcare provider and genetic counselor to develop an appropriate management plan.

Test Pricing and Details

Test Component Details
Test Name GARS1 Gene CMT2D NGS Genetic DNA Test
Discount Price $500 USD
Regular Price $700 USD
Turnaround Time 3 to 4 Weeks
Sample Type Blood, Extracted DNA, or One Drop Blood on FTA Card
Testing Method Next-Generation Sequencing (NGS) Technology

Pre-Test Requirements

Before scheduling your GARS1 Gene CMT2D NGS Genetic DNA Test, please ensure:

  • Complete clinical history documentation
  • Genetic counseling session to create family pedigree chart
  • Discussion of testing implications with healthcare provider
  • Understanding of potential outcomes and their significance

Nationwide Accessibility

We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network of certified collection centers ensures accessible genetic testing services nationwide.

Take Control of Your Neurological Health

Don’t let uncertainty about neurological symptoms affect your quality of life. The GARS1 Gene CMT2D NGS Genetic DNA Test provides definitive answers and empowers you with knowledge about your genetic health. Our team of neurological genetics specialists is ready to support you through every step of the testing process.

Call us today at +1(267) 388-9828 to schedule your genetic test or speak with our genetic counseling team. Take the first step toward understanding your neurological health with confidence and clarity.

Book your GARS1 Gene CMT2D NGS Genetic DNA Test now and receive comprehensive genetic insights from America’s leading neurological genetics laboratory. Our dedicated team ensures personalized care and thorough result interpretation to guide your healthcare journey.